drugset / Trial / NCT05752877
Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma
Unknown
12 enrolled
Second Affiliated Hospital of Soochow University
Soochow T-Maximun Biotechnology Co. LTD · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to estimate the safety, tolerance and initial efficacy of target IL-13Rα2 or B7-H3 UCAR-T cell injection in the treatment of patients with advanced glioma, as well as the pharmacokinetic characteristics of its metabolites after single and multiple administrations and the biomarkers related to efficacy, safety and drug metabolism.
Timeline
- Start
- 2021-05-01
- Primary completion
- 2026-04-30
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B7-H3 UCAR-T | Cell therapy | 1e+07 cells | Other |
| Subject | B7-H3 UCAR-T | Cell therapy | 5e+07 cells | Other |
| Subject | IL-13 Rα2 UCAR-T | Cell therapy | 1e+07 cells | Other |
| Subject | IL-13 Rα2 UCAR-T | Cell therapy | 5e+07 cells | Other |